Cowden syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| (10 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
*[[Pharmacological|Pharmacologic]] medical [[therapy]] is recommended among patients with [[cutaneous]] manifestations in [[cowden syndrome]] patients. | *[[Pharmacological|Pharmacologic]] medical [[therapy]] is recommended among patients with [[cutaneous]] manifestations in [[cowden syndrome]] patients.<ref name="pmid18021272">{{cite journal |vauthors=Jornayvaz FR, Philippe J |title=Mucocutaneous papillomatous papules in Cowden's syndrome |journal=Clin. Exp. Dermatol. |volume=33 |issue=2 |pages=151–3 |date=March 2008 |pmid=18021272 |doi=10.1111/j.1365-2230.2007.02602.x |url=}}</ref> | ||
**Preferred regimen (1): [[Acitretin]] for [[cutaneous]] manifestations. | **Preferred regimen (1): [[Acitretin]] 30 mg/day for [[cutaneous]] manifestations.<ref name="pmid21882176">{{cite journal |vauthors=Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR |title=Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) |journal=Cancer |volume=118 |issue=8 |pages=2128–37 |date=April 2012 |pmid=21882176 |pmc=3365547 |doi=10.1002/cncr.26374 |url=}}</ref><ref name="pmid15787821">{{cite journal |vauthors=Chen K, Craig JC, Shumack S |title=Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials |journal=Br. J. Dermatol. |volume=152 |issue=3 |pages=518–23 |date=March 2005 |pmid=15787821 |doi=10.1111/j.1365-2133.2005.06347.x |url=}}</ref><ref name="pmid7636533">{{cite journal |vauthors=Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, Vermeer BJ |title=Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study |journal=J. Clin. Oncol. |volume=13 |issue=8 |pages=1933–8 |date=August 1995 |pmid=7636533 |doi=10.1200/JCO.1995.13.8.1933 |url=}}</ref> | ||
***Side effects: | |||
****[[Teratogenicity]] | |||
****[[Xerostomia|Dryness]] of the [[eyes]] | |||
****Dryness of the [[nose]] | |||
****Dryness of the [[lips]] | |||
****[[Dry mouth|Dryness]] of the [[mouth]] | |||
****Dryness of the [[skin]] | |||
*** | |||
**[[Acitretin]] should be discontinued once the recurrence of skin [[Lesion|lesions]] are noted. | **[[Acitretin]] should be discontinued once the recurrence of skin [[Lesion|lesions]] are noted. | ||
**Preferred regimen (2): [[Sirolimus]]/ [[rapamycin]] Oral: Initial [[loading dose]]: 5 mg once, followed by a [[maintenance dose]] of 3 mg once daily<ref name="pmid18431376">{{cite journal |vauthors=Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM |title=Rapamycin treatment for a child with germline PTEN mutation |journal=Nat Clin Pract Oncol |volume=5 |issue=6 |pages=357–61 |date=June 2008 |pmid=18431376 |doi=10.1038/ncponc1112 |url=}}</ref><ref name="pmid18757421">{{cite journal |vauthors=Squarize CH, Castilho RM, Gutkind JS |title=Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin |journal=Cancer Res. |volume=68 |issue=17 |pages=7066–72 |date=September 2008 |pmid=18757421 |doi=10.1158/0008-5472.CAN-08-0922 |url=}}</ref><ref name="pmid24366516">{{cite journal |vauthors=Schmid GL, Kässner F, Uhlig HH, Körner A, Kratzsch J, Händel N, Zepp FP, Kowalzik F, Laner A, Starke S, Wilhelm FK, Schuster S, Viehweger A, Hirsch W, Kiess W, Garten A |title=Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies |journal=Pediatr. Res. |volume=75 |issue=4 |pages=527–34 |date=April 2014 |pmid=24366516 |doi=10.1038/pr.2013.246 |url=}}</ref> | |||
***MOA: Inhibiting [[cell proliferation]] by inhibiting [[mTOR]] | |||
***[[Sirolimus]] helps in decreasing [[mucocutaneous]] [[lesions]] and helps in decreasing the occurrence of [[mucocutaneous]] [[lesions]]. | |||
*[[Screening]] for multiple [[cancers]] should be effectively done in the patients with [[cowden syndrome]]. | *[[Screening]] for multiple [[cancers]] should be effectively done in the patients with [[cowden syndrome]]. | ||
Latest revision as of 19:33, 20 March 2019
|
Cowden syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cowden syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Cowden syndrome medical therapy |
|
Risk calculators and risk factors for Cowden syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Due to different phenotypes cowden syndrome is likely to be an underdiagnosed condition. Pharmacologic medical therapy is recommended among patients with cutaneous manifestations in cowden syndrome.
Medical Therapy
- Pharmacologic medical therapy is recommended among patients with cutaneous manifestations in cowden syndrome patients.[1]
- Preferred regimen (1): Acitretin 30 mg/day for cutaneous manifestations.[2][3][4]
- Acitretin should be discontinued once the recurrence of skin lesions are noted.
- Preferred regimen (2): Sirolimus/ rapamycin Oral: Initial loading dose: 5 mg once, followed by a maintenance dose of 3 mg once daily[5][6][7]
- MOA: Inhibiting cell proliferation by inhibiting mTOR
- Sirolimus helps in decreasing mucocutaneous lesions and helps in decreasing the occurrence of mucocutaneous lesions.
- Screening for multiple cancers should be effectively done in the patients with cowden syndrome.
References
- ↑ Jornayvaz FR, Philippe J (March 2008). "Mucocutaneous papillomatous papules in Cowden's syndrome". Clin. Exp. Dermatol. 33 (2): 151–3. doi:10.1111/j.1365-2230.2007.02602.x. PMID 18021272.
- ↑ Kadakia KC, Barton DL, Loprinzi CL, Sloan JA, Otley CC, Diekmann BB, Novotny PJ, Alberts SR, Limburg PJ, Pittelkow MR (April 2012). "Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251)". Cancer. 118 (8): 2128–37. doi:10.1002/cncr.26374. PMC 3365547. PMID 21882176.
- ↑ Chen K, Craig JC, Shumack S (March 2005). "Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials". Br. J. Dermatol. 152 (3): 518–23. doi:10.1111/j.1365-2133.2005.06347.x. PMID 15787821.
- ↑ Bavinck JN, Tieben LM, Van der Woude FJ, Tegzess AM, Hermans J, ter Schegget J, Vermeer BJ (August 1995). "Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study". J. Clin. Oncol. 13 (8): 1933–8. doi:10.1200/JCO.1995.13.8.1933. PMID 7636533.
- ↑ Marsh DJ, Trahair TN, Martin JL, Chee WY, Walker J, Kirk EP, Baxter RC, Marshall GM (June 2008). "Rapamycin treatment for a child with germline PTEN mutation". Nat Clin Pract Oncol. 5 (6): 357–61. doi:10.1038/ncponc1112. PMID 18431376.
- ↑ Squarize CH, Castilho RM, Gutkind JS (September 2008). "Chemoprevention and treatment of experimental Cowden's disease by mTOR inhibition with rapamycin". Cancer Res. 68 (17): 7066–72. doi:10.1158/0008-5472.CAN-08-0922. PMID 18757421.
- ↑ Schmid GL, Kässner F, Uhlig HH, Körner A, Kratzsch J, Händel N, Zepp FP, Kowalzik F, Laner A, Starke S, Wilhelm FK, Schuster S, Viehweger A, Hirsch W, Kiess W, Garten A (April 2014). "Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies". Pediatr. Res. 75 (4): 527–34. doi:10.1038/pr.2013.246. PMID 24366516.